Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Nosocomial Genotype 1 HCV Infection

Inclusion Criteria: * Body mass index (BMI) greater than or equal to 18 kg/m\^2. * HCV RNA greater than or equal to 1000 IU/mL at screening. * Documented acquisition of nosocomial genotype 1 HCV infection within 36 months from the screening visit. * Screening laboratory values within predefined thresholds. * Use of two effective contraception methods if female of childbearing potential or sexually active male. * Healthy according to medical history and physical examination with the exception of HCV diagnosis. Exclusion Criteria: * Unstable cardiac disease including subjects with active angina pectoris and/or hospitalization for a cardiac condition within 24 weeks prior to screening. * Prior exposure to an HCV NS5a inhibitor. * Pregnant or nursing female. * Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV). * History of solid organ transplantation. * Current or prior history of clinical hepatic decompensation. * History of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment, or compliance with the protocol. * Known hypersensitivity to LDV, SOF, or formulation excipients.